Evaluating important change in cutaneous disease activity as an efficacy measure for clinical trials in dermatomyositis

BACKGROUND: Patients may experience improved quality of life (QoL) without complete clearance of skin disease. The Cutaneous Dermatomyositis Disease Area and Severity Index-Activity (CDASI-A) score correlates with the Symptoms and Emotions subscales of Skindex-29, a measure of QoL, down to CDASI-A s...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Br J Dermatol
Hlavní autoři: Ahmed, S., Chakka, S., Concha, J., Krain, R., Feng, R., Werth, V.P.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6917999/
https://ncbi.nlm.nih.gov/pubmed/31206600
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjd.18223
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky